170 related articles for article (PubMed ID: 8513845)
1. Inhibition by paroxetine of desipramine metabolism in extensive but not in poor metabolizers of sparteine.
Brøsen K; Hansen JG; Nielsen KK; Sindrup SH; Gram LF
Eur J Clin Pharmacol; 1993; 44(4):349-55. PubMed ID: 8513845
[TBL] [Abstract][Full Text] [Related]
2. Single-dose kinetics of clomipramine: relationship to the sparteine and S-mephenytoin oxidation polymorphisms.
Nielsen KK; Brøsen K; Hansen MG; Gram LF
Clin Pharmacol Ther; 1994 May; 55(5):518-27. PubMed ID: 8181196
[TBL] [Abstract][Full Text] [Related]
3. The relationship between paroxetine and the sparteine oxidation polymorphism.
Sindrup SH; Brøsen K; Gram LF; Hallas J; Skjelbo E; Allen A; Allen GD; Cooper SM; Mellows G; Tasker TC
Clin Pharmacol Ther; 1992 Mar; 51(3):278-87. PubMed ID: 1531950
[TBL] [Abstract][Full Text] [Related]
4. Imipramine metabolism in relation to the sparteine oxidation polymorphism--a family study.
Madsen H; Hansen TS; Brøsen K
Pharmacogenetics; 1996 Dec; 6(6):513-9. PubMed ID: 9014200
[TBL] [Abstract][Full Text] [Related]
5. Steady-state concentrations of imipramine and its metabolites in relation to the sparteine/debrisoquine polymorphism.
Brøsen K; Klysner R; Gram LF; Otton SV; Bech P; Bertilsson L
Eur J Clin Pharmacol; 1986; 30(6):679-84. PubMed ID: 3533565
[TBL] [Abstract][Full Text] [Related]
6. Quinidine inhibits the 2-hydroxylation of imipramine and desipramine but not the demethylation of imipramine.
Brøsen K; Gram LF
Eur J Clin Pharmacol; 1989; 37(2):155-60. PubMed ID: 2792169
[TBL] [Abstract][Full Text] [Related]
7. The influence of the sparteine/debrisoquine genetic polymorphism on the disposition of dexfenfluramine.
Gross AS; Phillips AC; Rieutord A; Shenfield GM
Br J Clin Pharmacol; 1996 Apr; 41(4):311-7. PubMed ID: 8730977
[TBL] [Abstract][Full Text] [Related]
8. Imipramine metabolism in relation to the sparteine and mephenytoin oxidation polymorphisms--a population study.
Madsen H; Nielsen KK; Brøsen K
Br J Clin Pharmacol; 1995 Apr; 39(4):433-9. PubMed ID: 7640151
[TBL] [Abstract][Full Text] [Related]
9. Duplication of CYP2D6 predicts high clearance of desipramine but high clearance does not predict duplication of CYP2D6.
Bergmann TK; Bathum L; Brosen K
Eur J Clin Pharmacol; 2001 May; 57(2):123-7. PubMed ID: 11417443
[TBL] [Abstract][Full Text] [Related]
10. Imipramine demethylation and hydroxylation: impact of the sparteine oxidation phenotype.
Brøsen K; Otton SV; Gram LF
Clin Pharmacol Ther; 1986 Nov; 40(5):543-9. PubMed ID: 3769385
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of the selective serotonin reuptake inhibitor paroxetine: nonlinearity and relation to the sparteine oxidation polymorphism.
Sindrup SH; Brøsen K; Gram LF
Clin Pharmacol Ther; 1992 Mar; 51(3):288-95. PubMed ID: 1531951
[TBL] [Abstract][Full Text] [Related]
12. Extremely slow metabolism of amitriptyline but normal metabolism of imipramine and desipramine in an extensive metabolizer of sparteine, debrisoquine, and mephenytoin.
Brøsen K; Gram LF; Kragh-Sørensen P
Ther Drug Monit; 1991 Mar; 13(2):177-82. PubMed ID: 2053127
[TBL] [Abstract][Full Text] [Related]
13. Codeine and morphine in extensive and poor metabolizers of sparteine: pharmacokinetics, analgesic effect and side effects.
Poulsen L; Brøsen K; Arendt-Nielsen L; Gram LF; Elbaek K; Sindrup SH
Eur J Clin Pharmacol; 1996; 51(3-4):289-95. PubMed ID: 9010701
[TBL] [Abstract][Full Text] [Related]
14. First-pass metabolism of imipramine and desipramine: impact of the sparteine oxidation phenotype.
Brøsen K; Gram LF
Clin Pharmacol Ther; 1988 Apr; 43(4):400-6. PubMed ID: 3356084
[TBL] [Abstract][Full Text] [Related]
15. Duloxetine is both an inhibitor and a substrate of cytochrome P4502D6 in healthy volunteers.
Skinner MH; Kuan HY; Pan A; Sathirakul K; Knadler MP; Gonzales CR; Yeo KP; Reddy S; Lim M; Ayan-Oshodi M; Wise SD
Clin Pharmacol Ther; 2003 Mar; 73(3):170-7. PubMed ID: 12621382
[TBL] [Abstract][Full Text] [Related]
16. Metabolism, pharmacokinetics, and excretion of a highly selective N-methyl-D-aspartate receptor antagonist, traxoprodil, in human cytochrome P450 2D6 extensive and poor metabolizers.
Johnson K; Shah A; Jaw-Tsai S; Baxter J; Prakash C
Drug Metab Dispos; 2003 Jan; 31(1):76-87. PubMed ID: 12485956
[TBL] [Abstract][Full Text] [Related]
17. Theophylline metabolism in relation to antipyrine, debrisoquine, and sparteine metabolism.
Dahlqvist R; Bertilsson L; Birkett DJ; Eichelbaum M; Säwe J; Sjöqvist F
Clin Pharmacol Ther; 1984 Jun; 35(6):815-21. PubMed ID: 6734034
[TBL] [Abstract][Full Text] [Related]
18. Lack of relationship between quinidine pharmacokinetics and the sparteine oxidation polymorphism.
Nielsen F; Rosholm JU; Brøsen K
Eur J Clin Pharmacol; 1995; 48(6):501-4. PubMed ID: 8582470
[TBL] [Abstract][Full Text] [Related]
19. The stereoselective metabolism of fluoxetine in poor and extensive metabolizers of sparteine.
Fjordside L; Jeppesen U; Eap CB; Powell K; Baumann P; Brøsen K
Pharmacogenetics; 1999 Feb; 9(1):55-60. PubMed ID: 10208643
[TBL] [Abstract][Full Text] [Related]
20. Desipramine pharmacokinetics when coadministered with paroxetine or sertraline in extensive metabolizers.
Alderman J; Preskorn SH; Greenblatt DJ; Harrison W; Penenberg D; Allison J; Chung M
J Clin Psychopharmacol; 1997 Aug; 17(4):284-91. PubMed ID: 9241008
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
